Acorda Therapeutics Inc

Acorda Therapeutics — Q2 2023 Earnings Presentation

20 slides from Acorda Therapeutics's earnings presentation, Aug 8, 2023

  1. Slide 1: Acorda Therapeutics 2023 Q2 Earnings Call

    Acorda Therapeutics 2023 Q2 Earnings Call August 8, 2023

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Forward-Looking Statements This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are s

  3. Slide 3: Inbrija (levodopa inhalation powder) 42 mg capsules

  4. Slide 4: $8.3M Q2 2023 net revenue

    INBRIJA U.S. Net Sales – Q2 2023 $8.3M Q2 2023 net revenue 12% increase vs Q2 2022 4 2023 Q2 EARNINGS

  5. Slide 5: INBRIJA U.S. Net Sales Trends Since Launch

    INBRIJA U.S. Net Sales Trends Since Launch Net Sales $M 12.0 12%> vs Q2 22 10.0 10.4 9.4 9.0 8.0 8.3 7.8 7.9 7.4 6.0 6.8 6.4 6.1 5.6 4.0 5.0 4.7 5.0 4.4 3.7 2.0 3.0 0.0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2020 2021 2022 2023 5 2023 Q2 EARNINGS

  6. Slide 6: INBRIJA TRX Trends Since Launch

    INBRIJA TRX Trends Since Launch TRX $M 11%> vs Q2 22 4000 3500 3793 3464 3546 3000 3361 3319 3249 3300 3329 3110 3070 3125 3077 2992 2995 2500 2817 2761 2000 1915 1500 1000 500 79 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2019 2020 2021 2022 2023 6 2023 Q2 EARNINGS

  7. Slide 7: INBRIJA Cartons Dispensed – Trends Since Launch

    INBRIJA Cartons Dispensed – Trends Since Launch Cartons Dispensed to Patients $M 5%> vs Q2 22 12000 10000 11029 10135 9924 10102 9528 9362 9528 8000 8883 8737 9087 8514 8305 7857 7839 6000 6909 6955 4000 4198 2000 0 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2020 2021 2022 2023 7 2023 Q2 EAR

  8. Slide 8: INBRIJA Growth 1H 2023

    INBRIJA Growth 1H 2023 New prescription requests 42% vs 1H22 Total prescriptions 11% vs 1H22 Cartons dispensed 9% vs 1H22 8 2023 Q2 EARNINGS

  9. Slide 9: New Consumer Campaign: For the Fighters

    New Consumer Campaign: “FOR THE FIGHTERSTM” Launched July 25 Based on PwP feedback Importance of on-demand therapy Streaming commercial performing well ~8M views in first 4 months 165 physicians prescribed for the first time in 2023 since seeing the commercial 9 2023 Q2 EARNINGS

  10. Slide 10: INBRIJA Ex-U.S.

    INBRIJA Ex-U.S. Spain – launch ahead of expectations Germany – early issues being addressed China – regulatory update expected Q3-4 2023 – $2.5 million up-front payment received Latin America – Potential for up to 5 approvals and at least 1 launch in 2024 Conversations for additional countries in EU

  11. Slide 11: Ampyra

    \ ampyra’ aT < —— i] , EXTENDED RELEASE TABLETS Ampyra?

  12. Slide 12: $16.9M Q2 2023 net revenue

    AMPYRA U.S. Net Sales – Q2 2023 $16.9M Q2 2023 net revenue 7% decrease vs Q2 2022 12 2023 Q2 EARNINGS

  13. Slide 13: Maintaining Branded AMPYRA

    Maintaining Branded AMPYRA Net Sales, $MM $50.0 $44.2 $45.0 $40.6 $40.8 $40.0 $37.6 $35.0 $30.0 $27.2 $25.8 $25.3 $25.0 $21.8 $22.5 $20.3 $20.0 $21.1 $19.9 $18.8 $20.0 $18.2 $16.9 $14.9 $15.0 $12.6 $10.0 $5.0 $- Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2019 2019 2019 2019 2020 2020 2020

  14. Slide 14: Maintaining Branded AMPYRA

    Maintaining Branded AMPYRA • Annual net sales expected to stabilize at $60+M / year • Physician and patient brand loyalty has helped to maintain access • ~66% of all covered lives have access to AMPYRA1 • Field team continues to promote the brand • 159 HCPs have prescribed Brand in 2023 who did not

  15. Slide 15: Financials

    Financials 15 2023 Q2 EARNINGS

  16. Slide 16: Q2 2023 Financial Summary

    Q2 2023 Financial Summary Q/Q YTD YTD Y/Y ($ in millions) 2Q’23 2Q’22 Increase / June June Increase / (Decrease) 2023 2022 (Decrease) Net Global Inbrija 9.1 9.3 (0.2) (2.2%) 15.2 13.0 2.2 16.9% Revenue Net Ampyra Revenue 16.9 18.2 (1.3) (7.1%) 29.5 33.1 (3.6) (10.9%) R&D 1.6 1.5 0.1 6.7% 2.9 3.2 (0.

  17. Slide 17: Q2 2023 Ex-U.S. Revenue

    Q2 2023 Ex-U.S. Revenue INBRIJA ex-U.S. $ 0.8M FAMPYRA Royalty $ 2.9M Neurelis Inc. Royalty $ 0.8M • TOTAL EX-U.S.: $ 4.5M 17 2023 Q2 EARNINGS

  18. Slide 18: 2023 Updated Financial Guidance

    2023 Updated Financial Guidance INBRIJA U.S. Net Revenue $34M - $38M (prev $38M - $42M) AMPYRA U.S. Net Revenue $65M - $70M Adjusted OpEx $93M - 98M (prev $93M - $103M) Ending Cash Balance $39M - $44M (prev $43M - $47M) 18 2023 Q2 EARNINGS

  19. Slide 19: 2023 Priorities to Build Shareholder Value

    2023 Priorities to Build Shareholder Value ✓ Accelerate INBRIJA trajectory -Additional ex-U.S. INBRIJA agreements ✓ Maintain AMPYRA ✓ Continued fiscal discipline ✓ Communication with bondholders ✓ ARCUS collaborations 19 2023 Q2 EARNINGS

  20. Slide 20: LIFE. SCIENCE.

    LIFE. SCIENCE. °

Acorda Therapeutics — Q2 2023 Earnings Presentation on 6ix